• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Silo Pharma Inc (NQ: SILO )

    1.320 +0.040 (+3.13%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Silo Pharma Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
    World's Largest Psychedelics Conference Boasts 12K Attendees 
    Via Benzinga
    BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers
    Via Investor Brand Network
    Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
    Via ACCESSWIRE
    Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
    This month, Silo Pharma (NASDAQ: SILO) announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia an 
    Via Benzinga
    PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Revolutionizing Rheumatoid Arthritis Treatment: Psychedelics Biotech Co. Touts New Patent
    Psychedelics-focused biopharmaceutical company Silo Pharma, Inc. (NASDAQ: SILO) announced on Wednesday that the U.S. Patent and Trademark Office has issued Patent 16/825,371 titled "Peptide-Targeted... 
    Via Benzinga
    Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
    New patent expands Company’s intellectual property and technology rights portfolio 
    From Silo Pharma, Inc.
    Via GlobeNewswire
    Why Advanced Health Intelligence Shares Are Trading Higher By 111%; Here Are 20 Stocks Moving Premarket
    Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares gained 110.8% to $1.56 in pre-market trading after the company signed a Letter of Intention with UAE-Based e-script medicine management... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Wednesday morning! 
    Via InvestorPlace
    Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
    Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with... 
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Entry into Ketamine Implant Therapeutic Research Project
    Via Investor Brand Network
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate, Share Profile on Webull Platform
    Via Investor Brand Network
    Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement to Further Study Novel Joint Homing Peptide
    Via Investor Brand Network
    Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
    From Silo Pharma, Inc.
    Via GlobeNewswire
    Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
    Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
    Via Benzinga
    Stress-Related Mood Disorders And Alzheimer's: Can This Patented Ketamine Drug Help?
    Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and... 
    Via Benzinga
    PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Silo Pharma’s SPC-15 Awarded U.S. Patent to Protect Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
    ENGLEWOOD CLIFFS, NJ – May 9, 2023 – Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic... 
    Via FinancialNewsMedia
    Topics Intellectual Property
    Exposures Intellectual Property
    Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
    Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which... 
    Via FinancialNewsMedia
    Topics Intellectual Property
    Exposures Intellectual Property
    Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
    From Silo Pharma, Inc.
    Via GlobeNewswire
    Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
    LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Participation at Upcoming Psychedelic Drug Development Conference
    Via Investor Brand Network
    Silo Pharma to Present at Psychedelic Drug Development Conference
    From Silo Pharma, Inc.
    Via GlobeNewswire
    Stress, Anxiety, PTSD: 2 NASDAQ-Listed Drug Developers Advance Psychedelic-Inspired Meds
    Psychedelics biotech Silo Pharma Inc. (NASDAQ: SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD. 
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Development of Treatment for Anxiety-Related Disorders
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
    ENGLEWOOD CLIFFS, NJ – April 19, 2023 – Silo Pharma, Inc. (NASDAQ:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic... 
    Via FinancialNewsMedia
    Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
    Data to Support Alzheimer’s Study 
    From Silo Pharma, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.